Genespire Welcomes New Leadership with Karen Aiach-Pignet

Genespire Welcomes New Leadership with Karen Aiach-Pignet

Karen Aiach-Pignet Takes Charge

Genespire, a pioneering biotechnology firm, is thrilled to announce that Karen Aiach-Pignet has been appointed as the new Chief Executive Officer. Her appointment follows the departure of Dr. Julia Berretta, the previous CEO, marking a significant transition in the company’s leadership.

Bringing Extensive Experience in Gene Therapy

Karen's rich background in gene therapy is highlighted by her previous role as the founder of Lysogene, a global leader in the treatment of genetic neurodegenerative diseases. During her distinguished tenure there, she drove the innovative development of an adeno-associated virus (AAV) vector aimed at treating the rare condition, Sanfilippo Type A. Moreover, she led an international clinical trial that reached Phase 3, showcasing her ability to raise significant funding through various partnerships, including the successful listing of the company on the Euronext Stock Exchange.

Advancing Innovations at Genespire

Under Karen's leadership, Genespire aims to propel its primary candidate, GENE202, forward in clinical development. GENE202 targets methylmalonic acidemia (MMA), a severe genetic disorder that disrupts the body's metabolism of particular amino acids and fats, often leading to major health issues early in life. Currently, there are no available disease-modifying treatments for MMA, making Genespire’s approach essential in addressing the needs of pediatric patients suffering from this condition.

Karen Aiach-Pignet’s Vision for the Future

Speaking about her new role, Karen stated, "I wholeheartedly advocate for a future where patients with metabolic diseases receive the help they require. Leading Genespire to develop life-changing therapies for those in dire need is both a privilege and an immense responsibility. Our distinct ISLV technology, along with our dedicated investors and talented team, are all integral to our envisioned success. The newfound collaboration with Sofinnova Partners and other prestigious investors further strengthens our mission."

Valuable Praise from the Leadership Team

Joern Aldag, Chairman of Genespire, expressed his pride in the achievements of the team, extending gratitude to Dr. Julia Berretta for her remarkable contributions over the preceding four and a half years. "Karen’s extensive knowledge and dynamism in the realm of gene therapy for rare diseases and pediatric applications stand as an inspiration. Her determination and capacity for quick results will be key as we transition our lead lentiviral therapy into clinical testing," he emphasized.

Acknowledged Expertise in Healthcare and Research

Beyond her leadership roles, Karen has made meaningful contributions to the field by serving as a founding executive member of the International Rare Diseases Research Consortium and participating in the Paediatric Committee at the European Medicines Agency. Her commitment has also been recognized through various accolades, including the Ordre National du Merite, a prestigious French order of merit.

Continuing her professional development, Karen recently completed a program in Digital Health at Harvard Business School, complementing her early foundation in economics from the Institut d’Études Européennes at University Paris 8.

About Genespire

Genespire operates at the forefront of biotechnology, particularly focusing on developing off-the-shelf gene therapies utilizing immune shielded lentiviral vectors (ISLVs). These innovative vectors permit lifelong production of therapies directly within the patient’s liver, filling crucial gaps in treatment for inherited metabolic diseases. Established in 2020 by renowned figures in gene therapy, Genespire continues to grow as a promising spin-out of the SR-Tiget research institute, based in Milan, Italy. For more information, please reach out via email.

Frequently Asked Questions

Who is Karen Aiach-Pignet?

Karen Aiach-Pignet is the newly appointed CEO of Genespire, bringing a wealth of experience in gene therapy.

What significant achievements does Karen have in her career?

She founded Lysogene, led clinical trials for rare genetic disorders, and was influential in advancing treatments to market.

What is GENE202 and its significance?

GENE202 is Genespire's lead candidate targeting methylmalonic acidemia, a serious genetic disorder with no current disease-modifying treatments.

What technologies is Genespire developing?

Genespire specializes in off-the-shelf gene therapies using immune shielded lentiviral vectors (ISLVs) to treat genetic diseases.

How can I learn more about Genespire?

Additional information about Genespire’s initiatives and research can be found through their contact channels.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.